| Indicator 1: Percentage of specimens reported as MTB detected (MTB positivity rate) |
Number of specimens reported as MTB detected RIF resistance not detected, RIF resistance detected, and RIF indeterminate in 1 month |
Total number of specimens tested in 1 month |
13.42–24.61%[13–18] |
| Indicator 2: Percentage of specimens reported as MTB detected; rifampicin resistance detected (RIF resistance rate) |
Number of specimens reported as MTB detected RIF resistance detected in 1 month |
Total number of MTB detected in 1 month |
5.8% (2.8–8.4%)[12] |
| Indicator 3: Percentage of specimens reported as MTB detected; rifampicin indeterminate (RIF resistance indeterminate rate) |
Number of specimens reported as MTB detected RIF indeterminate in 1 month |
Total number of MTB detected in 1 month |
8.9%[17] 13.6%[13] |
| Indicator 4: Percentage of specimens with error results (Error rate) |
Number of specimens with error results in 1 month |
Total number of specimens tested in 1 month |
<3%[11] |
| Indicator 5: Percentage of specimens with invalid results (Invalid rate |
Number of specimens with invalid results in 1 month |
Total number of specimens tested in 1 month |
<1%[11] |
| Indicator 6: Percentage of specimens with “no results” (No result rate) |
Number of specimens with “no results” in 1 month |
Total number of specimens tested in 1 month |
<1%[11] |
| Indicator 7: Percentage of Xpert MTB/RIF results reported within TAT for results (Within TAT rate) |
Number Xpert MTB/RIF results reported within the target TAT (2–24hrs) for results |
Total number of Xpert MTB/RIF results reported |
90%[11] |
